Based on the result of Qiagen’s initial research, the CMM may also provide laboratory-based genomics and proteomics services to assist Qiagen in the development and validation of new molecular diagnostic tests.
Daniel Farkas, executive director of CMM, said: “The speed and analytical depth of XenoBase coupled with the CMM’s access to clinical samples can give Qiagen a competitive advantage in the development of new molecular diagnostic tests, especially in the field of oncology.”